Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
企業コードCODX
会社名Co-Diagnostics Inc
上場日Jul 12, 2017
最高経営責任者「CEO」Mr. Dwight H. Egan
従業員数132
証券種類Ordinary Share
決算期末Jul 12
本社所在地2401 S. Foothill Dr. Suite D
都市SALT LAKE CITY
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号84109
電話番号18014381036
ウェブサイトhttp://codiagnostics.com/
企業コードCODX
上場日Jul 12, 2017
最高経営責任者「CEO」Mr. Dwight H. Egan
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし